New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT03502733
First seen Oct 31, 2025 · Last updated Jun 12, 2026 · Updated 36 times
Summary
This early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. Copanlisib blocks proteins that help tumors grow, while the immunotherapies boost the body's immune system to attack cancer cells. The goal is to find a safe dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.